7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T60353 | Glucocerebrosidase-IN-1 | ||
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC 50 of 29.3 μM and a K i of 18.5 μM. Due to GCase involvement in pathological disorders consequent to enzym... | |||
T78671 | Glucocerebrosidase-IN-1 hydrochloride | Glucosidase | |
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent, selective GCase (glucocerebrosidase) inhibitor with IC50 and Ki values of 29.3 μM and 18.5 μM, respectively. It is utilized in the research of Gaucher dis... | |||
T37440 | C2 Adamantanyl Galactosylceramide (d18:1/2:0) | ||
C2 Adamantanyl Galactosylceramide (d18:1/2:0) (AdaGalCer) is a bioactive sphingolipid. It reduces globotriaosylceramide 3 synthesis from exogenous lactosylceramide in microsomes. AdaGalCer stimulates recombinant glucocer... | |||
T78573 | Glucocerebrosidase | GCase,Glucosylceramidase | Endogenous Metabolite |
Glucocerebrosidase (Glucosylceramidase; GBA), a lysosomal enzyme, catalyzes the hydrolysis of the β-glucosidic linkage in glucocerebroside (GC) to yield glucose and ceramide [1]. | |||
T80994 | Therapeutic agent-1 | ||
Therapeutic Agent-1, a heteroaryl compound, serves as an enzyme replacement therapy to enhance glucocerebrosidase activity in the treatment of Gaucher disease [1]. | |||
T37928 | 13C6 Glucosylsphingosine (d18:1) | ||
13C6 Glucosylsphingosine (d18:1) is an isotopically enriched form of 1-β-D-glucosylsphingosine (d18:1) that is intended for use as an internal standard for the quantification of 1-β-D-glucosylsphingosine by GC- or LC-MS.... | |||
T38213 | 1-β-D-Glucosylsphingadienine (d18:2 (4E,8E)) | 1-β-D-Glucosylsphingadienine (d18:2 (4E,8E)) | |
1-β-D-Glucosylsphingadienine is a glucosylsphingosine, which are deacetylated lysolipid derivatives of glucosylcerebrosides . They are formed when sphingosines undergo glucosidation by UDP-glucose. Glucosylsphingosines c... |